Literature DB >> 7518483

Conjugation of recombinant reverse transcriptase of HIV-1 to beta-D-galactosidase from Escherichia coli for ultrasensitive enzyme immunoassay (immune complex transfer enzyme immunoassay) of anti-HIV-1 IgG.

K Hashinaka1, S Hashida, A Saitoh, A Nakata, H Shinagawa, S Oka, K Shimada, E Ishikawa.   

Abstract

Recombinant reverse transcriptase (RT) of HIV-1 was conjugated to beta-D-galactosidase from Escherichia coli in three different ways. Maleimide groups were introduced into beta-D-galactosidase molecules using N,N'-o-phenylenedimaleimide in the absence (method I) or presence (method II) of N-ethylmaleimide or into beta-D-galactosidase molecules, which had been treated with excess of 4,4'-dithiodipyridine to block thiol groups, using N-succinimidyl-6-maleimidohexanoate (method III). Subsequently, the maleimide groups were reacted with thiol groups introduced into recombinant RT molecules using N-succinimidyl-S-acetylmercaptoacetate. The conjugates were tested by a sensitive enzyme immunoassay (immune complex transfer enzyme immunoassay). The immune complex consisting of 2,4-dinitrophenyl-bovine serum albumin-recombinant RT conjugate, anti-HIV-1 IgG and recombinant RT-beta-D-galactosidase conjugate was captured by polystyrene beads coated with (anti-2,4-dinitrophenyl group) IgG, eluted with N epsilon-2,4-dinitrophenyl-L-lysine and transferred to polystyrene beads with (anti-human IgG gamma chain) IgG. The conjugate prepared by method III, which showed the least polymerization, the least loss of the specific enzyme activity and the lowest nonspecific binding, improved the sensitivity of the enzyme immunoassay for anti-HIV-1 IgG approximately 30-fold compared with RT-horseradish peroxidase conjugate.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7518483     DOI: 10.1016/0022-1759(94)90105-8

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  6 in total

1.  Rapid formation of the immune complexes on solid phase in the immune complex transfer enzyme immunoassays for HIV-1 p24 antigen and antibody IgGs to HIV-1.

Authors:  S Ishikawa; S Hashida; K Hashinaka; A Adachi; S Oka; E Ishikawa
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

Review 2.  More reliable diagnosis of infection with human immunodeficiency virus type 1 (HIV-1) by detection of antibody IgGs to pol and gag proteins of HIV-1 and p24 antigen of HIV-1 in urine, saliva, and/or serum with highly sensitive and specific enzyme immunoassay (immune complex transfer enzyme immunoassay): a review.

Authors:  S Hashida; K Hashinaka; S Ishikawa; E Ishikawa
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

3.  Preparations of recombinant HIV-1 p66 antigen to improve the specificity of immune complex transfer enzyme immunoassay of antibody IgG to HIV-1 reverse transcriptase.

Authors:  K Hashinaka; I Nishikata; S Hashida; A Adachi; S Oka; E Ishikawa
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

4.  Recombinant p51 as antigen in an immune complex transfer enzyme immunoassay of immunoglobulin G antibody to human immunodeficiency virus type 1.

Authors:  K Hashinaka; S Hashida; I Nishikata; A Adachi; S Oka; E Ishikawa
Journal:  Clin Diagn Lab Immunol       Date:  2000-11

5.  Earlier detection of human immunodeficiency virus type 1 p24 antigen and immunoglobulin G and M antibodies to p17 antigen in seroconversion serum panels by immune complex transfer enzyme immunoassays.

Authors:  S Hashida; S Ishikawa; K Hashinaka; I Nishikata; S Oka; E Ishikawa
Journal:  Clin Diagn Lab Immunol       Date:  2000-11

6.  Immune complex transfer enzyme immunoassay that is more sensitive and specific than western blotting for detection of antibody immunoglobulin G to human immunodeficiency virus type 1 in serum with recombinant pol and gag proteins as antigens.

Authors:  S Hashida; K Hashinaka; I Nishikata; S Oka; K Shimada; A Saito; A Takamizawa; H Shinagawa; S Yano; H Kojima
Journal:  Clin Diagn Lab Immunol       Date:  1995-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.